KCM
IART icon

Karp Capital Management’s Integra LifeSciences IART Stock Holding History

Karp Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,025
Closed -$344K – 168
2021
Q3 		$344K Buy
+5,025
New +$355K 0.05% 132

Other funds holding IART

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Karp Capital Management's IART Position: Q4 2021 in Review

Karp Capital Management sold out of Integra LifeSciences (IART) in Q4 2021, closing a stake of 5,025 shares — an estimated $344K sold.

Karp Capital Management first reported a position in IART in Q3 2021 and held it in 1 quarter. The position peaked at $344K in Q3 2021. 277 funds tracked by Wall St. Rank hold IART as of Q4 2021.

  • Karp Capital Management reported no remaining Integra LifeSciences position as of Q4 2021 after selling out during the quarter.
  • Karp Capital Management sold 5,025 Integra LifeSciences shares in Q4 2021, an estimated $344K.
  • Karp Capital Management first reported a position in Integra LifeSciences in Q3 2021 and held it in 1 quarter.
  • Karp Capital Management's Integra LifeSciences position peaked at $344K in Q3 2021.
  • 277 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2021.

Based on Karp Capital Management's 13F filing for Q4 2021, filed 4 Feb 2022.